Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- David Russell, M.D., Ph.D
Invicro
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Invicro (site 100), 60 Temple Street, 8th Floor
New Haven, Connecticut, United States
- the Neurocognitive Institute (site 103), 111 Howard Blvd., Suite 204
Mount Arlington, New Jersey, United States
- Columbia University Irving Center for Clinical and Translational Research (site 105), 622 West 168th Street, Ph-10th Floor
New York, New York, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 22 Mar 2022
- Primary completion
- 30 Sept 2024
- Completion
- 28 Feb 2025
- Last update posted
- 15 Jun 2023
- Registered enrollment
- 130
- Registry id
- NCT04141150
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.